LOTIS-2 follow-up analysis: updated results from a phase 2 study of loncastuximab tesirine (Lonca) in relapsed or refractory diffuse large B-cell lymphoma
Authors
Kahl, B. S.Hamadani, M.
Caimi, P. F.
Carlo-Stella, C.
Ai, W. Y.
Alderuccio, J. P.
Ardeshna, K. M.
Hess, B.
Radford, John A
Solh, M.
Stathis, A.
Feingold, J.
Ungar, D.
Qin, Y. J.
He, S.
Zinzani, P. L.
Affiliation
Department of Medicine, Oncology Division, Washington University, St. Louis, MO, USAIssue Date
2021